Pinc PeptideThe girly peptide research blog

Brain & sleep · Evidence tier B

DSIP (emideltide)

Delta sleep-inducing peptide · Emideltide (WHO international nonproprietary name, proposed 1993) · Emideltide acetate (salt form) · Delta sleep peptide · Deltaran (Russian nasal medicine containing DSIP)

DSIP is a lab-made copy of a 9-amino-acid peptide first found in rabbits, sold online for sleep12. Small trials from 1981 to 1992 disagreed, and two independent placebo-controlled trials found little or no benefit234.

Last reviewed · First published · 43 sources · 29 min read · By the Pinc Peptide editors

Illustration: a glass vial with a pink label reading DSIP
Illustration, not a real product: an empty glass vial (photo: Missouri Historical Society, public domain) with our label. See every vial.

Quick answers

What is it?
A lab-made chain of 9 amino acids, named delta sleep-inducing peptide after the deep-sleep brain waves it boosted in rabbits1. It is sold online as injections and nasal sprays for sleep and stress2.
Does it work?
Not clearly. One research group reported longer, less broken sleep in small studies56. Two other placebo-controlled trials in insomnia found little or no benefit34. FDA called the evidence ‘inconclusive and at best preliminary’2.
Is it safe?
Unclear. In studies, 209 people got it into a vein for 1 to 15 days, mostly without serious problems2. In a withdrawal study, 3 of 107 had serious reactions, 2 of them low blood pressure2. FDA found no safety data for injections under the skin2.
Is it legal?
Not approved in the US, and US pharmacies may not make it27. In July 2026, FDA’s advisers voted 7 to 6 against allowing it8. Russia approves a DSIP nose-drop medicine, sold without prescription910. Sport’s banned list does not name it1112.
What is in the vials?
Little is known. Finnrick, a testing service, lists only 4 tests in 2026: 2 passed, 1 failed and 1 was incomplete13. FDA said lab certificates sent with the nominations lacked impurity tests, and one listed a formula that matches no form of DSIP2.

What it is

DSIP (delta sleep-inducing peptide) is a chain of 9 amino acids: tryptophan, alanine, glycine, glycine, aspartic acid, alanine, serine, glycine and glutamic acid114. Its international nonproprietary name, the generic name the World Health Organization assigns, is emideltide; WHO’s 1993 listing describes it as a sedative14. It was named for the slow ‘delta’ brain waves of deep sleep, which it increased when infused into rabbits’ brains1. How it might work is unclear. FDA’s 2026 review says its sleep effects in rats appear to involve the body’s opioid system: it does not seem to bind opioid receptors itself but has been reported to trigger the release of the body’s own opioids2. Whether the body makes DSIP at all is unsettled. A 2006 review noted that no gene, precursor protein or receptor for it had been found, and called the idea of DSIP as a sleep factor ‘extremely poorly documented and still weak’15. The same review’s authors reported that, in their own rabbit and rat studies, some lab-made variants of DSIP promoted deep sleep but DSIP itself did not15. Even the Russian label for a DSIP medicine says its mechanism of action is unknown9. Enzymes in blood break it down within minutes2.

The Schoenenberger and Monnier group in Basel, Switzerland, isolated DSIP in 1977 from blood draining the brains of rabbits put to sleep by electrical stimulation of the thalamus, a relay deep in the brain, then worked out its sequence and made it in the lab11516. Human studies began in 1981, mostly by Schneider-Helmert and colleagues217. The drug company Hoffmann-La Roche supplied DSIP for a 1984 withdrawal study, and the most recent sleep trial in FDA’s review dates from 19922. In Russia it is sold as Deltaran, nose drops made by a state research institute in Saint Petersburg10. In the US, Wells Pharmacy Network and LDT Health Solutions asked FDA to allow pharmacies to compound it, then withdrew; FDA reviewed it anyway for its July 2026 advisory meeting2.

Benefits: what the research shows

Every placebo-controlled human study gave DSIP into a vein (IV), usually 25 nmol/kg (about 21 µg/kg), and the sleep trials FDA reviewed ran from 1981 to 19922. Results split by research group. Schneider-Helmert and colleagues reported benefits. In 6 healthy volunteers, a morning dose raised sleep over the next 130 minutes by 59% compared with placebo17. In a randomized, double-blind crossover in 6 people with chronic insomnia, sleep was longer and less interrupted, though time to fall asleep did not change; FDA notes the paper reported only ‘tendencies’ for some measures and gave no placebo figures25. The group later reported ‘complete normalization’ of disturbed sleep after 4 consecutive injections, and normal sleep patterns in 18 middle-aged and older insomniacs by a week after 6 doses1920. In 14 people with severe insomnia given 7 nightly doses, time to fall asleep fell from 58.4 to 27.6 minutes and total sleep rose from 313 to 385 minutes. FDA notes there was no placebo group of insomniacs: results were compared with the patients’ own baseline nights and with healthy volunteers given placebo26. Two independent double-blind trials did not confirm a useful effect. A crossover in 6 insomniacs given 4 nightly doses found no significant improvement over baseline or placebo nights and called the change ‘of little clinical significance’23. A trial in 16 chronic insomniacs, half given a sugar-solution placebo, found weak effects that could partly reflect a chance change in the placebo group; the authors concluded that short-term treatment ‘is not likely to be of major therapeutic benefit’4. FDA’s 2026 review called the insomnia evidence ‘inconclusive and at best preliminary’ and found no study of injection under the skin, the route proposed for compounding2. Data for other uses are uncontrolled. In an open study of 107 inpatients in alcohol or opioid withdrawal, doctors and nurses rated symptoms as gone or much improved in 97% of evaluable opioid patients and 87% of alcohol patients, but some opioid patients who had responded relapsed into anxiety and marked insomnia within 24 to 72 hours of stopping221. In a 1998 open study of 7 people in opioid detox, only 2 completed the injection schedule, and both needed another drug for insomnia2. An open study reported normal sleep for 3 to 7 months in 6 of 7 people with severe insomnia22, a single narcolepsy case had fewer sleep attacks23, and a pilot that compared 7 people with chronic pain episodes against their own earlier pain levels reported less pain in 624. A 2014 study reported that a nasal DSIP product, 0.0003 g of DSIP a day for 2 months, sped the recovery of the brain’s response to visual signals after a bright-light test in 15 people with diabetic eye damage; its abstract describes no placebo group25. Claims that DSIP lowers stress hormones are not settled: in small placebo-controlled studies in healthy men, one found lower ACTH (a pituitary stress hormone) with no change in cortisol, and another found no effect on ACTH or cortisol2627. The most recent controlled human study, from 2009, found the opposite of sedation: in 24 women under general anesthesia, half of them given saline, DSIP raised heart rate and made anesthesia lighter28. Longevity claims rest on animals. In a lifelong study of Deltaran in mice, average lifespan did not change, although the longest-lived 10% lived 17.1% longer and tumors were 2.6 times less common29. FDA says that because the product also contains glycine, which has reported anti-cancer effects, the result does not show DSIP is free of cancer risk2.

Key human studies

StudyDesignPeopleDose and routeResult
Bes et al., Neuropsychobiology 19924PubMed · DOI Double-blind, placebo-controlled, matched-pairs parallel-group trial over 5 nights in a sleep laboratory, in chronic insomnia 16 25 nmol/kg IV in the afternoon before nights 3, 4 and 5 (placebo: glucose solution) Sleep efficiency was higher and time to fall asleep shorter with DSIP than placebo, but the effects were weak and could partly reflect a chance change in the placebo group; subjective sleep quality did not change. The authors concluded that short-term treatment ‘is not likely to be of major therapeutic benefit’4.
Monti et al., Int J Clin Pharmacol Res 19873PubMed Double-blind, placebo-controlled crossover with overnight sleep recordings, in severe chronic insomnia (randomized, per FDA) 6 25 nmol/kg IV over 4 minutes on 4 nights Time to fall asleep and time awake fell and total sleep rose by about 20 minutes, but not significantly compared with baseline or placebo nights; the few significant differences from placebo were already present before treatment. The authors called the improvement ‘of little clinical significance’23.
Schneider-Helmert and Schoenenberger, Experientia 19815PubMed · DOI Randomized, double-blind, placebo-controlled crossover in middle-aged people with chronic insomnia 6 25 nmol/kg IV over 4 minutes before bedtime Sleep was longer and less interrupted from the second hour after injection for up to 6 hours, after a slight arousing effect in the first hour, with no daytime sedation. Time to fall asleep did not change, and FDA notes results were given as p-values without placebo figures25.
Schneider-Helmert, Eur Neurol 19876PubMed · DOI Double-blind study with placebo nights before and after treatment; FDA classes it as externally controlled because results were compared with healthy volunteers given placebo, not with a placebo group of insomniacs 14 30 nmol/kg IV on 7 nights in a row Time to fall asleep fell from 58.4 to 27.6 minutes, time awake after falling asleep from 120.8 to 65.6 minutes, and total sleep rose from 313 to 385 minutes, with effects lasting into the first placebo night after treatment. Daytime alertness and performance also improved26.
Dick et al., Eur Neurol 198421PubMed · DOI Open, uncontrolled study in hospital inpatients in alcohol or opioid withdrawal 107 25 nmol/kg IV, on request or every 6 to 8 hours, up to 6 injections a day for up to 6 days Doctors and nurses rated symptoms as gone or markedly improved in 97% of evaluable opioid and 87% of evaluable alcohol patients, with anxiety easing more slowly. Some opioid patients who had responded relapsed into anxiety and marked insomnia within 24 to 72 hours of stopping. Headaches, and in 2 patients low blood pressure, were reported221.
Pomfrett et al., Eur J Anaesthesiol 200928PubMed · DOI Randomized controlled study in women under general anesthesia (propofol, then isoflurane); 12 received saline 24 One IV dose of 25, 50 or 100 nmol/kg while awake and another under anesthesia The authors expected DSIP to deepen anesthesia, but it raised heart rate, lowered heart-rate variability and, at 25 nmol/kg, reduced delta brain waves and raised the bispectral index, a sign of lighter anesthesia28.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

All placebo-controlled studies gave DSIP into a vein, most often 25 nmol/kg (about 21 µg/kg) as a slow injection, over 4 minutes in several trials, as a single dose or on 3 to 7 nights; some studies used 30 or 35 nmol/kg2346. Withdrawal studies gave up to 6 injections a day for up to 6 days2. In total, FDA counted 209 people given 25 to 150 nmol/kg for 1 to 15 days2. A 2009 anesthesia study gave 25, 50 or 100 nmol/kg twice, once while awake and again under anesthesia28. FDA found no human study of injection under the skin, the form sold in the US2. For nasal use, Russia’s Deltaran label lists 1 to 3 ampoules of 0.3 mg a day for 5 to 10 days10, and a 2014 study gave 0.0003 g of DSIP a day for 2 months25.

In animal studies

As reported. Rabbits: 6 nmol/kg infused into the brain’s fluid spaces over 3.5 minutes raised delta brain-wave activity by about 35%16. Mice: Deltaran at 2.5 µg per mouse (about 100 µg/kg) under the skin on 5 days each month, from 3 months of age until death29. Half-life studies gave single IV doses of about 0.05 to 0.1 mg/kg to dogs, 2.0 mg/kg to rats and 0.2 mg/kg to a monkey2.

What users report Anecdotal · not validated · not a recommendation

A dosing-chart site (updated 28 September 2026) lists 100 to 300 µg injected under the skin once a day, with an ‘advanced’ range up to 500 µg that it says rests on anecdote. The same page says the small, older human studies, often using IV doses, do not validate its schedule41.

Half-life
About 8 minutes in blood plasma2FDA’s 2026 review gives DSIP a plasma half-life of 8 minutes2. After IV doses in animals it was 3 to 6 minutes in dogs and about 2 to 3 minutes in rats and a monkey; in human serum in the lab it lasted 5 to 10 minutes239. Blood enzymes break it down from its starting (amino) end into smaller fragments240. FDA found no data on how long it lasts after injection under the skin2.
Routes
  • Intravenous injection (all placebo-controlled human studies, 1981 to 2009)
  • Nasal drops (Russia’s approved Deltaran; one small 2014 human study of a nasal DSIP product)
  • Nasal spray (marketed by US clinics and retailers, per FDA; no human data found on these products)
  • Subcutaneous injection (the route proposed for US compounding and shown in dosing charts; no human data found; used in a lifelong mouse study)
  • Infusion into the brain’s fluid spaces (the rabbit studies that defined DSIP)

Every dose studied for DSIP (emideltide), with sources →

Quality and the gray market

What testing finds

Finnrick, an independent testing service, lists 4 DSIP tests from 2 sellers between 26 April 2026 and 3 August 2026: 2 passed, 1 failed and 1 was incomplete under its ‘purity focus’ standard (purity of at least 99.5% and dose within 35% of the label)13. That is too few tests to judge the market. FDA’s review found that the certificates of analysis (lab reports) sent with the withdrawn nominations gave no impurity limits or results, mentioned no tests for microbes or bacterial toxins (endotoxin) and gave no information on clumping (aggregation); one listed a molecular formula that ‘does not correspond to any emideltide structure’2. FDA added that the free form dissolves in water only to about 0.5 mg/mL, so it is unclear how the proposed 1 mg/mL injection could be made; the acetate salt dissolves more easily2. No FDA sampling, recall or media lab test of DSIP was found.

How it is sold

In pages it viewed in 2024, FDA found US integrative neurology clinics, concierge medical services, medical spas, wellness clinics and online retailers marketing DSIP injections and nasal sprays for sleep disorders, stress, pain, cancer, Alzheimer’s and Parkinson’s disease, and alcohol and drug detox2. One site sold a ‘ready to use’ 2 mg/mL injection kit described as ‘pharmaceutical grade’ and ‘made in the USA’, with a ‘complementary telemed consult’; FDA could not tell whether any of these products were compounded2. Online sellers also offer vials labeled for research: one US seller’s shop page listed a 10 mg DSIP vial at $60, marked down from $94.99, while stating that its products are ‘for Research, Development use only’ and ‘Not for Human consumption of any kind’ (accessed 5 October 2026)42. A peptide reference site that earns commissions from sellers says effects are ‘often noticeable from the first dose’ and promises ‘no tolerance or dependence’43. Finnrick had logged only 4 DSIP tests by 3 August 202613. Earlier, a Kentucky compounding pharmacy distributed DSIP among other unapproved drugs from 2018 to 202033, and Health Canada lists DSIP among injectable peptides it has seized37.

Side effects and risks

  • Little safety data for how it is used now: the human data come from short IV courses in 209 people, and FDA found no safety data for injection under the skin and no long-term data2.
  • Blood pressure drops: in a 1984 withdrawal study, 2 people developed low blood pressure at the start of their first injection, and one of the 3 people with serious effects had ‘progressive hypotension’ after a second injection; 9 others had short-lived sweating, headache, nausea or vertigo2. Russia’s label for its nasal product advises against use with severe bradycardia (a very slow heart rate)10.
  • Immune reactions: FDA says a 9-amino-acid peptide injected under the skin may pose a significant risk of unwanted immune responses (immunogenicity), possibly amplified by clumping and impurities, and that injection under the skin generally carries more of this risk than IV use230.
  • Opioid-system effects: FDA says DSIP’s sleep effects in rats appear to involve the body’s opioid system, that by releasing the body’s own opioids it could have addictive properties, and that the agency found no lab or animal studies of DSIP’s abuse potential2.
  • Drug interactions: FDA says drugs that block one of the enzymes that break DSIP down, such as captopril (a blood-pressure medicine), could raise active DSIP levels2.
  • Pregnancy and young people: Russia’s label rules out use during pregnancy or breastfeeding and under age 1810.
  • Wrong or impure contents: one nomination’s lab certificate listed a formula matching no form of DSIP, 1 of 4 Finnrick tests failed, and Health Canada warns that unauthorized peptides may contain too much, too little or none of the active ingredient, or contaminants21337.
  • Missing reports: FDA’s review found no reports involving emideltide in FAERS (the FDA Adverse Event Reporting System) through 3 March 2024, and no relevant case reports in the medical literature2. At the July 2026 meeting, FDA reminded its advisers that 503A compounders are not required to report adverse events, so no reports does not mean no harm8.
  • Legal risk: a Kentucky compounding pharmacy was sentenced in 2021 after distributing DSIP and other unapproved drugs, and Health Canada has seized DSIP products3437.

Documented harms

  • 1984In an open study of IV DSIP in 107 hospital patients in alcohol or opioid withdrawal, 3 had serious adverse effects: 2 developed low blood pressure at the start of their first injection, and 1 had repeated 15-minute episodes of discomfort with sweating and nausea. One of these 3 had ‘progressive hypotension’ after a second injection. Nine others had short-lived sweating, headache, nausea or vertigo. The authors linked some side effects to vials, supplied by Hoffmann-La Roche, that did not dissolve well. FDA summarized these reports in its 2026 review2.

Questions people ask

Is DSIP FDA approved?

No. FDA has not approved DSIP (emideltide) for any use, and US pharmacies may not compound it27. In Russia, a DSIP nasal medicine called Deltaran is registered and sold without prescription910.

Does DSIP actually help you sleep?

The evidence is weak and conflicting. One research group reported better sleep in small studies, but two other placebo-controlled trials found little or no benefit, and FDA called the evidence ‘inconclusive and at best preliminary’234. Every sleep trial gave DSIP into a vein; none tested injections under the skin or the nasal sprays sold in the US2.

Why did the FDA panel vote against DSIP?

On 24 July 2026, FDA’s compounding advisory committee voted 6 for and 7 against adding DSIP to the list of substances pharmacies may use, with 1 abstention835. Members who voted no cited low-quality efficacy evidence, poor characterization of the substance, the existence of approved therapies and an uncertain dosing regimen8. FDA staff had also recommended against it2.

Is DSIP banned in sports?

It is not named on WADA’s 2026 or 2027 Prohibited List1112. The catch-all class S0 covers only substances with no government approval for human use, and Russia has approved a DSIP nasal medicine, so by our reading DSIP is likely allowed911. WADA has not ruled on it and urges ‘utmost caution’ with unnamed peptides, so athletes should not rely on this reading38.

What is the half-life of DSIP?

About 8 minutes in blood plasma, according to FDA’s 2026 review2. In dogs it was 3 to 6 minutes, and blood enzymes break it down quickly240.

Is DSIP a natural sleep hormone?

Not proven. DSIP was isolated from rabbit blood in 197716. But a 2006 review noted that no gene, precursor protein or receptor for it had been found, and called the idea of DSIP as a sleep factor ‘extremely poorly documented and still weak’15.

What is still unknown

  • Is Deltaran’s Russian registration current in the official State Register of Medicines (GRLS), and is DSIP approved anywhere else? Two Russian drug references list it as registered (Vidal shows a registration dated 31 July 2026 that replaced an earlier one), but the register itself could not be checked, and FDA’s 2026 review said emideltide is not registered in any country it searched.
  • Does WADA regard DSIP as approved, and so outside S0? WADA has not named it either way; our ‘not prohibited’ reading rests on the Russian approval.
  • Will FDA follow its advisers’ 24 July 2026 vote against DSIP? As of 5 October 2026 FDA had posted no minutes, and the vote counts come from the FDA Law Blog and AJMC, not FDA.
  • What happens to DSIP in the body after injection under the skin or use as a nasal spray? No human data were found for either route as sold in the US.
  • Does the body make DSIP at all? No gene, precursor protein or receptor has been identified.
  • What is DSIP’s addiction potential? FDA found no studies, despite its opioid-dependent effects in animals.
  • What did the vials Finnrick tested contain? Only pass, fail and incomplete results are public; purity and content figures need a login.
  • What is the legal status of DSIP in the UK and EU, and of ‘deltalicin’, the nasal DSIP product in a 2014 study? Not verified.
  • Has DSIP been tested for sleep with modern methods? No trial is registered on ClinicalTrials.gov (searched 5 October 2026), and no controlled sleep trial after 1992 was found.

Sources

  1. 1Characterization of a delta-electroencephalogram (-sleep)-inducing peptide Proceedings of the National Academy of Sciences, Mar 1977. pubmed.ncbi.nlm.nih.gov
  2. 2FDA Evaluation of Emideltide-Related Bulk Drug Substances (Emideltide (Free Base) and Emideltide Acetate), PCAC briefing document U.S. Food and Drug Administration, 11 May 2026. fda.gov
  3. 3Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs International Journal of Clinical Pharmacology Research, 1987. pubmed.ncbi.nlm.nih.gov
  4. 4Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study Neuropsychobiology, 1992. pubmed.ncbi.nlm.nih.gov
  5. 5The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep Experientia, 1981. pubmed.ncbi.nlm.nih.gov
  6. 6Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia European Neurology, 1987. pubmed.ncbi.nlm.nih.gov
  7. 7Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  8. 8The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 28 Jul 2026. thefdalawblog.com
  9. 9Дельтаран (Deltaran), nasal lyophilizate 0.3 mg: instructions for use Vidal Russia drug reference, 4 Jun 2026. vidal.ru
  10. 10Дельтаран (Deltaran), nasal lyophilizate 0.3 mg: instructions, doses, side effects RLS (Register of Medicinal Products of Russia), 22 Sep 2026. rlsnet.ru
  11. 11World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  12. 12World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  13. 13DSIP Safety Testing Results & Vendor Ratings Finnrick, 3 Aug 2026. finnrick.com
  14. 14Proposed International Nonproprietary Names: List 70 (WHO Drug Information, Vol. 7, No. 4) World Health Organization, 1993. cdn.who.int
  15. 15Delta sleep-inducing peptide (DSIP): a still unresolved riddle Journal of Neurochemistry, Apr 2006. pubmed.ncbi.nlm.nih.gov
  16. 16The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide Pflügers Archiv: European Journal of Physiology, 6 Sep 1978. pubmed.ncbi.nlm.nih.gov
  17. 17Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior International Journal of Clinical Pharmacology, Therapy, and Toxicology, Aug 1981. pubmed.ncbi.nlm.nih.gov
  18. 18Delta Sleep-Inducing Peptide (PubChem CID 68816) PubChem, National Center for Biotechnology Information, accessed 5 Oct 2026. pubchem.ncbi.nlm.nih.gov
  19. 19Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep Neuropsychobiology, 1983. pubmed.ncbi.nlm.nih.gov
  20. 20Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs European Neurology, 1986. pubmed.ncbi.nlm.nih.gov
  21. 21DSIP in the treatment of withdrawal syndromes from alcohol and opiates European Neurology, 1984. pubmed.ncbi.nlm.nih.gov
  22. 22A clinical trial with DSIP European Neurology, 1984. pubmed.ncbi.nlm.nih.gov
  23. 23Effects of DSIP on narcolepsy European Neurology, 1984. pubmed.ncbi.nlm.nih.gov
  24. 24Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study European Neurology, 1984. pubmed.ncbi.nlm.nih.gov
  25. 25Using deltalicin for the treatment of patients with diabetic retinopathy (in Russian) Eksperimental’naia i Klinicheskaia Farmakologiia, 2014. pubmed.ncbi.nlm.nih.gov
  26. 26Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man Psychoneuroendocrinology, 1989. pubmed.ncbi.nlm.nih.gov
  27. 27Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion Psychoneuroendocrinology, 1995. pubmed.ncbi.nlm.nih.gov
  28. 28Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia European Journal of Anaesthesiology, Feb 2009. pubmed.ncbi.nlm.nih.gov
  29. 29Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice Mechanisms of Ageing and Development, Jun 2003. pubmed.ncbi.nlm.nih.gov
  30. 30Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
  31. 31Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
  32. 32ClinicalTrials.gov search for ‘emideltide’, ‘DSIP’ or ‘delta sleep-inducing peptide’ (0 studies) ClinicalTrials.gov, accessed 5 Oct 2026. clinicaltrials.gov
  33. 33Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs U.S. Attorney’s Office, Eastern District of Kentucky, 29 Oct 2020. justice.gov
  34. 34Nicholasville Compounding Pharmacy and Its Owner Sentenced for Unlawful Distribution of Prescription Drugs U.S. Attorney’s Office, Eastern District of Kentucky, 24 Feb 2021. justice.gov
  35. 35FDA Panel Backs 6 Peptides for Compounding AJMC (The American Journal of Managed Care), 31 Jul 2026. ajmc.com
  36. 36July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
  37. 37Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
  38. 38Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  39. 39Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs Neuroendocrinology, Jul 1984. pubmed.ncbi.nlm.nih.gov
  40. 40Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum Peptides, Jul 1987. pubmed.ncbi.nlm.nih.gov
  41. 41DSIP (5 mg Vial) Dosage Protocol PeptideDosages, 28 Sep 2026. peptidedosages.com
  42. 42Shop (product listing including ‘DSIP (10mg)’) Ascension Peptides (vendor), accessed 5 Oct 2026. ascensionpeptides.com (seller page, deliberately not linked)
  43. 43DSIP: How It Works, Mechanism & Evidence (2026) The Peptide Catalog, 18 Apr 2026. thepeptidecatalog.com

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.